Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Outcomes of Advanced Gastroesophageal Cancer Patients with Equivocal HER2 Expression with or without ERBB2 Gene Amplification

Oncology(2020)10.1159/000509148Source: DataRank Database

Outcomes of Advanced Gastroesophageal Cancer Patients with Equivocal HER2 Expression with or without ERBB2 Gene Amplification is a research paper published in Oncology (2020). On theSindex it has a DataRank of 0.165. It has been cited 2 times.

N/A

0.165DataRank · unranked

Scored on demand from live citation data

Open Access2 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (2 grants)Impact (FWCI 0.08)OA: greenTopics (57)IDs (PubMed, PMC, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 100%Citation Network 0%

Base Score Contribution

0.165

From this paper's citation signal

Citation Network Contribution

Citation network not refreshed for this result

This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.

Learn more about DataRank methodology →

Authors (8)

Xuemei Wang ORCID,Jane E. Rogers ORCID,Allison Trail,Meina Zhao ORCID,Mariela Blum‐Murphy

Live enrichment

PubMed:32998149 PMC:PMC10604547 OpenAlex:https://openalex.org/W3089470805

NCI NIH HHS

Grant: R01 CA138671

NCI NIH HHS

Grant: P30 CA016672

FWCI

0.08

Citation Percentile

0.4%

Citation Trend

2022

2025

greenLicense: https://karger.com/pages/terms-and-conditions

repositoryhttps://pmc.ncbi.nlm.nih.gov/articles/PMC10604547/pdf/nihms-1938171.pdf

publisherhttps://karger.com/ocl/article-pdf/98/12/884/3908655/000509148.pdf

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/10604547

journalhttps://doi.org/10.1159/000509148

Fields of Study

HER2/EGFR in Cancer ResearchGastric Cancer Management and OutcomesColorectal Cancer Treatments and StudiesAdultAgedAged, 80 and overBiomarkers, TumorEsophageal NeoplasmsFemaleGene AmplificationGene Expression Regulation, NeoplasticHumansImmunohistochemistryIn Situ Hybridization, FluorescenceMaleMiddle AgedOncogenesProgression-Free SurvivalErb-b2 Receptor Tyrosine KinasesStomach Neoplasms

MeSH Terms

Progression-Free SurvivalAdultAgedAged, 80 and overEsophageal NeoplasmsFemaleGene AmplificationHumansImmunohistochemistryMaleMiddle AgedOncogenesStomach NeoplasmsBiomarkers, TumorGene Expression Regulation, NeoplasticIn Situ Hybridization, FluorescenceErb-b2 Receptor Tyrosine KinasesReceptor, ErbB-2

Keywords

MedicineInternal medicineImmunohistochemistryOncologyFluorescence in situ hybridizationConfidence intervalCohortCancerRetrospective cohort studyAdenocarcinomaGastroenterologyPathologyGeneBiologySurvivalFISHerbB2Her2Gastroesophageal Cancer

Sustainable Development Goals

SDG 0: Good health and well-being